牛牛AI助手已提取核心信息
Chewy, Inc. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) on January 18, 2024, to recast certain financial information reflecting the operations of Chewy Pharmacy KY as part of its consolidated financial statements. This follows the transactions with affiliates of BC Partners Advisors LP, which resulted in Chewy Pharmacy KY becoming an indirect wholly-owned subsidiary of Chewy. The recast financial information does not represent a restatement of previously issued financial statements but is intended to reflect the operations of Chewy Pharmacy KY in the company's financials for the fiscal years ended January 30, 2022, and January 29, 2023, as well as the quarterly periods ended April 30, July 30, and October 29, 2023. The report includes both GAAP and certain non-GAAP financial measures, with reconciliations provided for non-GAAP measures. The filing is meant to be read in conjunction with the company's previous reports and other SEC filings.
Chewy, Inc. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) on January 18, 2024, to recast certain financial information reflecting the operations of Chewy Pharmacy KY as part of its consolidated financial statements. This follows the transactions with affiliates of BC Partners Advisors LP, which resulted in Chewy Pharmacy KY becoming an indirect wholly-owned subsidiary of Chewy. The recast financial information does not represent a restatement of previously issued financial statements but is intended to reflect the operations of Chewy Pharmacy KY in the company's financials for the fiscal years ended January 30, 2022, and January 29, 2023, as well as the quarterly periods ended April 30, July 30, and October 29, 2023. The report includes both GAAP and certain non-GAAP financial measures, with reconciliations provided for non-GAAP measures. The filing is meant to be read in conjunction with the company's previous reports and other SEC filings.
Chewy, Inc.已于2024年1月18日向美国证券交易委员会（SEC）提交了8-K表的最新报告，将反映肯塔基州Chewy Pharmacy运营的某些财务信息作为其合并财务报表的一部分。在此之前，肯塔基州Chewy Parners Advisors LP的关联公司进行了交易，这导致肯塔基州Chewy Pharmacy成为Chewy的间接全资子公司。重估的财务信息并不代表先前发布的财务报表的重述，但旨在在公司截至2022年1月30日和2023年1月29日的财年以及截至2023年4月30日、7月30日和10月29日的季度财务中反映肯塔基州Chewy Pharmacy的运营情况。该报告包括公认会计原则和某些非公认会计准则财务指标，并对非公认会计准则指标进行了对账。该文件应与该公司先前的报告和其他美国证券交易委员会文件一起阅读。
Chewy, Inc.已于2024年1月18日向美国证券交易委员会（SEC）提交了8-K表的最新报告，将反映肯塔基州Chewy Pharmacy运营的某些财务信息作为其合并财务报表的一部分。在此之前，肯塔基州Chewy Parners Advisors LP的关联公司进行了交易，这导致肯塔基州Chewy Pharmacy成为Chewy的间接全资子公司。重估的财务信息并不代表先前发布的财务报表的重述，但旨在在公司截至2022年1月30日和2023年1月29日的财年以及截至2023年4月30日、7月30日和10月29日的季度财务中反映肯塔基州Chewy Pharmacy的运营情况。该报告包括公认会计原则和某些非公认会计准则财务指标，并对非公认会计准则指标进行了对账。该文件应与该公司先前的报告和其他美国证券交易委员会文件一起阅读。
有用
没用